期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

P27^(kip1)、Jab1、Skp2的生物学功能及其与非霍奇金淋巴瘤发生、发展关系的研究进展 被引量：2

下载PDF
导出
摘要 非霍奇金淋巴瘤(NHL)是具有高度异质性的淋巴造血系统的恶性疾病,近年来很多国家NHL的发病率有一定增高趋向。P27kip1是一种抑癌基因,参与细胞周期调控;c-Jun激活区结合蛋白1(Jab1)参与P27kip1蛋白的出核转运过程;S期激酶相关蛋白2(Skp2)能够特异性识别Thr-187磷酸化的P27kip1分子,介导P27kip1的多聚泛素化及随后的蛋白水解。Jab1、Skp2功能异常导致P27kip1水平下降、功能缺失,可能参与NHL的发生、发展。
作者 马燕 赵建美
机构地区 南通大学附属医院
出处 《山东医药》 CAS 北大核心 2015年第28期108-110,共3页 Shandong Medical Journal
基金 江苏省人力资源和社会保障厅第九批"六大人才高峰"资助项目(WSN-061)
关键词 非霍奇金淋巴瘤 P27KIP1 c-Jun激活区结合蛋白1 S期激酶相关蛋白2
分类号 R733.1 [医药卫生—肿瘤]
  • 相关文献

参考文献20

  • 1Xinmiao Yang,Ning Zhang,Zeliang Shi,Zhangyu Yang,Xichun Hu.Histone deacetylase inhibitor suberoyl bis-hydroxamic acid suppressescell proliferation and induces apoptosis in breast cancer cells[J]. Molecular Medicine Reports . 2015 (4)
  • 2Christian R. Salazar,Nicole Anayannis,Richard V. Smith,Yanhua Wang,Missak Haigentz,Madhur Garg,Bradley A. Schiff,Nicole Kawachi,Jordan Elman,Thomas J. Belbin,Michael B. Prystowsky,Robert D. Burk,Nicolas F. Schlecht.Combined P16 and human papillomavirus testing predicts head and neck cancer survival[J]. Int. J. Cancer . 2014 (10)
  • 3Shinpei Tamaki,Yasuhito Tokumoto.Overexpression of cyclin dependent kinase inhibitor P27/Kip1 increases oligodendrocyte differentiation from induced pluripotent stem cells[J]. In Vitro Cellular & Developmental Biology - Animal . 2014 (8)
  • 4Chen Sun,Jing Zhao,Yecheng Jin,Congzhe Hou,Wen Zong,Tingting Lu,Huashun Li,Jiangang Gao.PTEN regulation of the proliferation and differentiation of auditory progenitors through the PTEN/PI3K/Akt-signaling pathway in mice[J]. NeuroReport . 2014 (3)
  • 5Rebecca Siegel,Jiemin Ma,Zhaohui Zou,Ahmedin Jemal.Cancer statistics, 2014[J]. CA A Cancer Journal for Clinicians . 2014 (1)
  • 6Min Fei,Qinglei Hang,Sicong Hou,Songbin He,Changgeng Ruan.Adhesion to fibronectin induces p27 Kip1 nuclear accumulation through down-regulation of Jab1 and contributes to cell adhesion-mediated drug resistance (CAM-DR) in RPMI 8,226 cells[J]. Molecular and Cellular Biochemistry . 2014 (1-2)
  • 7Seung YeonHa,Chang HunLee,Hee KyungChang,SunheeChang,Kun YoungKwon,Eun HeeLee,Mee SookRoh,BoramSeo.Differential expression of forkhead box M1 and its downstream cyclin‐dependent kinase inhibitors p27<sup>kip1</sup> and p21<sup>waf1/cip1</sup> in the diagnosis of pulmonary neuroendocrine tumours[J]. Histopathology . 2012 (5)
  • 8Akihiro Yoshida,Noriko Yoneda-Kato,Martina Panattoni,Ruggero Pardi,Jun-ya Kato.CSN5/Jab1 controls multiple events in the mammalian cell cycle[J]. FEBS Letters . 2010 (22)
  • 9Berber D. Roorda,Arja ter Elst,Frank J.G. Scherpen,Tiny G.J. Meeuwsen-de Boer,Willem A. Kamps,Eveline S.J.M. de Bont.VEGF-A promotes lymphoma tumour growth by activation of STAT proteins and inhibition of p27 KIP1 via paracrine mechanisms[J]. European Journal of Cancer . 2009 (5)
  • 10Chen-Feng Qi,Shao Xiang,Min Sun Shin,Xingpei Hao,Chang Hoon Lee,Jeff X. Zhou,Ted A. Torrey,Janet W. Hartley,Torgny N. Fredrickson,Herbert C. Morse.Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas[J]. Leukemia Research . 2005 (2)

共引文献48

同被引文献34

  • 1Chamberlain MC.Treatment of primary CNS lymphoma(PCNSI.)following successful treatment of systemic non-Hodgkin s lymphoma(NHL):a case series[J].J Neurooncol.2013,113(1):27-32.DOI:10.1007/s11060-013-1085-7.
  • 2Lukens JN,Nasta SD,Fram B,et al.Outcomes after involved-field radiation therapy(IFRT)with or without rituximah in patients with early-stage low-grade non-Hodgkin lymphoma(NHL)staged with CT and PET[J].Am J Clin Oncol,2014,37(1):35-40.DOI:10.l097/COC.0b013e31826106c9.
  • 3Lewis TS,Mccormick RS,Emmerton K,et al.Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in nonHodgkin lymphoma[J].Clin Cancer Res,2011,17(14):4672-4681.
  • 4Lee S,Knox A.Zeng IS,et al.Primary prophylaxis with granulocyte colony-stimulating factor(GCSF)reduces the incidence of febrile neutropenia in patients with non-Hodgkin lymphoma(NHL)receiving CHOP chemotherapy treatment without adversely affecting their quality of Life:cost-benefit and quality of Life analysis[J].Support Care Cancer,2013.21(3):84l-846.DOI:10.I007/s00520-012-1589-2.
  • 5Orlowski R Z,Voorhees P M,Garcia R A,et al.Phase I trial ofthe proteasome inhibitor bortezomib and pegy Lated liposomal doxorubi-ein in patients with advanced hematologic malignancies[J].Blood,2005,105(8):3058-3065.
  • 6Visani G,Guiducci B,D’ Adamo F,et al.Cyclophosphamide,pegylated liposome doxorubicin,vincristine and prednisone(GDOP) plusrituximab is effective and well tolerated in poor performancestatus elderly patients with Non-Hodgkin lymphoma[J].Leukemia lymphoma,2005,46(3):477-479.
  • 7Illidge T,Specht L,Yahalom J,et al.Modern radiation therapy for nodal non-hodgkin lymphoma-target definition and dose guidelines from the international lymphoma radiation oncology group[J].Int J Radiat Oncol Biol Phys,2014,89(1):49-58.
  • 8Strobbe L,Van der Schans,S A,Heijker S,et al.Evaluation of a panel of expert pathologists:review of the diagnosis and histological classification of Hodgkin and non-Hodgkin lymphomas in a population-based cancer registry[J].Leukemia and lymphoma,2014,55(5):1018-1022.
  • 9Hagemeister F B,Rodriguez M A,Deitcher S R,et al.Long term results of a phase 2 study of vincristine sulfate liposome injection(MarqiboR) substituted for non-liposomal vincristine in cyclophosphamide,doxorubicin,vincristine,prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas[J].Blood,2013,122(21):3033.
  • 10Deng Z,Yan F,Jin Q,et al.Reversal of multidrug resistance phenotype in human breast cancer cells using doxorubicin-liposome-microbubble complexes assisted by ultrasound[J].J Control Release,2014,174(1):109-116..

引证文献2

二级引证文献16

山东医药
2015年 第28期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部